CELLDEX THERAPEUTICS INC (CLDX)
US15117B2025 - Common Stock
Taking everything into account, CLDX scores 4 out of 10 in our fundamental rating. CLDX was compared to 568 industry peers in the Biotechnology industry. CLDX has a great financial health rating, but its profitability evaluates not so good. CLDX is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year CLDX has reported negative net income.
CLDX had a negative operating cash flow in the past year.
CLDX had negative earnings in each of the past 5 years.
In the past 5 years CLDX always reported negative operating cash flow.
1.2 Ratios
CLDX has a better Return On Assets (-18.72%) than 79.47% of its industry peers.
The Return On Equity of CLDX (-19.61%) is better than 85.31% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -18.72% | ||
| ROE | -19.61% | ||
| ROIC | N/A |
ROA(3y)-26.03%
ROA(5y)-28.97%
ROE(3y)-28.07%
ROE(5y)-33.37%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
CLDX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
CLDX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for CLDX has been increased compared to 1 year ago.
The number of shares outstanding for CLDX has been increased compared to 5 years ago.
CLDX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
An Altman-Z score of 24.94 indicates that CLDX is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 24.94, CLDX belongs to the top of the industry, outperforming 94.69% of the companies in the same industry.
There is no outstanding debt for CLDX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 24.94 |
ROIC/WACCN/A
WACC11.91%
2.3 Liquidity
CLDX has a Current Ratio of 24.27. This indicates that CLDX is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of CLDX (24.27) is better than 96.64% of its industry peers.
CLDX has a Quick Ratio of 24.27. This indicates that CLDX is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of CLDX (24.27) is better than 96.64% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 24.27 | ||
| Quick Ratio | 24.27 |
3. Growth
3.1 Past
CLDX shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 2.65%.
CLDX shows a strong growth in Revenue. In the last year, the Revenue has grown by 128.28%.
CLDX shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -6.32% yearly.
EPS 1Y (TTM)2.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%20.99%
Revenue 1Y (TTM)128.28%
Revenue growth 3Y-2.47%
Revenue growth 5Y-6.32%
Sales Q2Q%110.35%
3.2 Future
The Earnings Per Share is expected to grow by 12.56% on average over the next years. This is quite good.
The Revenue is expected to grow by 142.48% on average over the next years. This is a very strong growth
EPS Next Y14.98%
EPS Next 2Y-6.47%
EPS Next 3Y-9.81%
EPS Next 5Y12.56%
Revenue Next Year76.31%
Revenue Next 2Y1.74%
Revenue Next 3Y2.26%
Revenue Next 5Y142.48%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for CLDX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CLDX. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
CLDX's earnings are expected to decrease with -9.81% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-6.47%
EPS Next 3Y-9.81%
5. Dividend
5.1 Amount
CLDX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
CELLDEX THERAPEUTICS INC
NASDAQ:CLDX (12/20/2024, 8:02:37 PM)
After market: 25.14 0 (0%)25.14
-0.24 (-0.95%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners108.88%
Inst Owner Change3.53%
Ins Owners1.49%
Ins Owner Change0.1%
Market Cap1.67B
Analysts84.44
Price Target68.44 (172.24%)
Short Float %11.65%
Short Ratio7.75
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)8.32%
Min EPS beat(2)6.71%
Max EPS beat(2)9.93%
EPS beat(4)3
Avg EPS beat(4)7.03%
Min EPS beat(4)-9.41%
Max EPS beat(4)20.89%
EPS beat(8)6
Avg EPS beat(8)3.28%
EPS beat(12)7
Avg EPS beat(12)0.75%
EPS beat(16)8
Avg EPS beat(16)-3.27%
Revenue beat(2)2
Avg Revenue beat(2)238.1%
Min Revenue beat(2)198.5%
Max Revenue beat(2)277.69%
Revenue beat(4)3
Avg Revenue beat(4)193.38%
Min Revenue beat(4)-83.3%
Max Revenue beat(4)380.62%
Revenue beat(8)6
Avg Revenue beat(8)188.86%
Revenue beat(12)7
Avg Revenue beat(12)110.23%
Revenue beat(16)9
Avg Revenue beat(16)135.56%
PT rev (1m)-0.45%
PT rev (3m)0.15%
EPS NQ rev (1m)0.74%
EPS NQ rev (3m)2.68%
EPS NY rev (1m)1.37%
EPS NY rev (3m)1.71%
Revenue NQ rev (1m)26.69%
Revenue NQ rev (3m)15.99%
Revenue NY rev (1m)13.07%
Revenue NY rev (3m)52.35%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 167.18 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 2.12 | ||
| P/tB | 2.2 | ||
| EV/EBITDA | N/A |
EPS(TTM)-2.57
EYN/A
EPS(NY)-3.3
Fwd EYN/A
FCF(TTM)-2.41
FCFYN/A
OCF(TTM)-2.38
OCFYN/A
SpS0.15
BVpS11.85
TBVpS11.44
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -18.72% | ||
| ROE | -19.61% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-26.03%
ROA(5y)-28.97%
ROE(3y)-28.07%
ROE(5y)-33.37%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.01
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 58.76% | ||
| Cap/Sales | 18.35% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 24.27 | ||
| Quick Ratio | 24.27 | ||
| Altman-Z | 24.94 |
F-Score4
WACC11.91%
ROIC/WACCN/A
Cap/Depr(3y)54.75%
Cap/Depr(5y)43.74%
Cap/Sales(3y)43.61%
Cap/Sales(5y)34.43%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)2.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%20.99%
EPS Next Y14.98%
EPS Next 2Y-6.47%
EPS Next 3Y-9.81%
EPS Next 5Y12.56%
Revenue 1Y (TTM)128.28%
Revenue growth 3Y-2.47%
Revenue growth 5Y-6.32%
Sales Q2Q%110.35%
Revenue Next Year76.31%
Revenue Next 2Y1.74%
Revenue Next 3Y2.26%
Revenue Next 5Y142.48%
EBIT growth 1Y-29.2%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-23.96%
EBIT Next 3Y-20.46%
EBIT Next 5YN/A
FCF growth 1Y-62.21%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-63.57%
OCF growth 3YN/A
OCF growth 5YN/A